The atypical cannabinoid O‐1602 stimulates food intake and adiposity in rats

  title={The atypical cannabinoid O‐1602 stimulates food intake and adiposity in rats},
  author={Adenis D{\'i}az-Arteaga and Maria Jesus Vazquez and Rafael V{\'a}zquez-Mart{\'i}nez and Marina R. Pulido and Juan Su{\'a}rez and Douglas A. Vel{\'a}squez and M. L{\'o}pez and Ruth Alexandra Ross and Fernando Rodr{\'i}guez de Fonseca and Francisco Javier Berm{\'u}dez-Silva and Mar{\'i}a M. Malag{\'o}n and Carlos Di{\'e}guez and Rub{\'e}n Nogueiras},
Aims: Cannabinoids are known to control energy homeostasis. Atypical cannabinoids produce pharmacological effects via unidentified targets. We sought to investigate whether the atypical cannabinoid O‐1602 controls food intake and body weight. 

Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta‐cells, isolated pancreatic islets and mice

The effects of various GPR55 agonists on glucose homeostasis are assessed using a novel lipid sensing receptor activated by both cannabinoid endogenous ligands (endocannabinoids) and other non‐cannabinoid lipid transmitters.

A potential role for GPR55 in gastrointestinal functions

Effects of GPR18 Ligands on Body Weight and Metabolic Parameters in a Female Rat Model of Excessive Eating

The presented preliminary data support the idea that the search for selective GPR18 antagonists for the treatment of obesity might be promising and that the G PR18 agonist is likely to affect body weight by inducing gastrointestinal disorders such as nausea.

Potential Metabolic and Behavioural Roles of the Putative Endo-
cannabinoid Receptors GPR18, GPR55 and GPR119 in Feeding

The present review attempts to summarize the lines of evidence supporting the potential role of GPR18, GPR55 and GPR119 in metabolism and feeding control that may explain some of the divergent effects and puzzling data re-lated to cannabinoid research.

The Role of Atypical Cannabinoid Ligands O-1602 and O-1918 on Skeletal Muscle Homeostasis with a Focus on Obesity

O-1602 does not alter mRNA expression of key pathways important for skeletal muscle energy homeostasis in obesity, and O-1918 appears to alter markers of oxidative capacity and fatty acid metabolism in C2C12 myotubes only.

Endocannabinoid and nitric oxide interaction mediates food intake in neonatal chicken

The results suggest that there is an interaction between endogenous nitric oxide and the cannabinoidergic system on feeding behaviour which is mediated via CB1 receptors in the neonatal chicken.

Off-Target Cannabinoid Effects Mediated by GPR55

This commentary aims to summarize GPR55 expression data and speculate on potential therapeutic exploitation of this enigmatic orphan receptor.

New vistas for treatment of obesity and diabetes? Endocannabinoid signalling and metabolism in the modulation of energy balance

A detailed account of the known physiological role of the ECS in energy balance is provided, and how recent studies have delivered novel insights into the potential targeting of this system as a therapeutic means for treating obesity and related metabolic disorders is explored.

GPR55‐dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans

The effects of GPR55 ligands on intracellular calcium levels and insulin secretion from islets isolated from GPR 55 knockout mice, age‐matched wildtype mice and human pancreas are evaluated.



Bimodal control of stimulated food intake by the endocannabinoid system

Using combined genetic and pharmacological approaches in mice, it is found that ventral striatal CB1 receptors exerted a hypophagic action through inhibition of GABAergic transmission, and brainCB1 receptors modulating excitatory transmission mediated the well-known orexigenic effects of cannabinoids.

Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.

The atypical cannabinoid O‐1602 protects against experimental colitis and inhibits neutrophil recruitment

The data demonstrate that O‐1602 is protective against experimentally induced colitis and inhibits neutrophil recruitment independently of CB1, CB2, and GPR55 receptors, and represents a novel class of therapeutics that may be useful for the treatment of inflammatory bowel diseases.

Receptors for NPY and PACAP differ in expression and activity during adipogenesis in the murine 3T3‐L1 fibroblast cell line

A large number of neuropeptides have been found to be involved in the regulation of food intake in the central nervous system, but they might also act on peripheral fat tissue via neuropePTide receptors via Neuropeptide receptors.

Food Intake‐independent Effects of CB1 Antagonism on Glucose and Lipid Metabolism

It is suggested that in diet‐induced obesity, chronic CB1 antagonism causes weight loss and improves insulin sensitivity by diverting lipids from storage toward utilization, independent of the anorectic action of the drug.

The orphan receptor GPR55 is a novel cannabinoid receptor

The endocannabinoid system functions through two well characterized receptor systems, the CB1 and CB2 receptors. Work by a number of groups in recent years has provided evidence that the system is

Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors

This first demonstration of anandamide-induced, CB1-mediated, overeating provides important evidence for the involvement of a central cannabinoid system in the normal control of eating.

Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system?

  • G. Kunos
  • Biology, Medicine
    The American journal of medicine
  • 2007